Compare HRMY & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | PENN |
|---|---|---|
| Founded | 2017 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | 1996 |
| Metric | HRMY | PENN |
|---|---|---|
| Price | $31.05 | $16.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $44.11 | $20.83 |
| AVG Volume (30 Days) | 793.3K | ★ 4.2M |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | $868,453,000.00 | ★ $6,362,900,000.00 |
| Revenue This Year | $19.75 | $6.85 |
| Revenue Next Year | $12.88 | $3.83 |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $11.65 |
| 52 Week High | $40.87 | $20.61 |
| Indicator | HRMY | PENN |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 55.09 |
| Support Level | $25.92 | $16.60 |
| Resistance Level | $30.96 | $18.13 |
| Average True Range (ATR) | 1.47 | 0.85 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 35.36 | 58.67 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.